Literature DB >> 21326270

Study to investigate the potential of probiotics in children attending school.

D Merenstein1, J Gonzalez, A G Young, R F Roberts, M E Sanders, S Petterson.   

Abstract

BACKGROUND/
OBJECTIVES: To determine if consumption of yogurt containing a high dose of probiotic (1×10(10) colony-forming unit per 100 ml), Bifidobacterium animalis subsp. lactis (B. lactis), decreases absences in children 2-4 years attending daycare/school centers. SUBJECTS/
METHODS: We conducted a double-blinded, randomized, placebo-controlled, allocation concealment clinical trial in the Washington, DC area. Our active intervention was a strawberry yogurt-based drink supplemented with B. lactis BB-12. The placebo was indistinguishable from the active drink, differing only in absence of the probiotic BB-12.
RESULTS: A total of 172 children between the ages of 2 and 4 from the Washington, DC area were enrolled. The primary outcome, missed days of school because of illness per 100 days, was similar in both the active (2.54 days absent/100 school days) and control groups (2.42 days absent/100 school days) (P=0.873).
CONCLUSIONS: The probiotic-containing yogurt-based beverage studied did not decrease absences because of illnesses in daycare/school for healthy children ages 2-4 years.
© 2011 Macmillan Publishers Limited All rights reserved

Entities:  

Mesh:

Year:  2011        PMID: 21326270     DOI: 10.1038/ejcn.2010.290

Source DB:  PubMed          Journal:  Eur J Clin Nutr        ISSN: 0954-3007            Impact factor:   4.016


  9 in total

1.  Safety of Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12-supplemented yogurt in healthy adults on antibiotics: a phase I safety study.

Authors:  Daniel J Merenstein; Tina P Tan; Aleksey Molokin; Keisha Herbin Smith; Robert F Roberts; Nawar M Shara; Mihriye Mete; Mary Ellen Sanders; Gloria Solano-Aguilar
Journal:  Gut Microbes       Date:  2015

2.  Consumption of Bifidobacterium animalis subsp. lactis BB-12 in yogurt reduced expression of TLR-2 on peripheral blood-derived monocytes and pro-inflammatory cytokine secretion in young adults.

Authors:  Huicui Meng; Zhaoyong Ba; Yujin Lee; Jiayu Peng; Junli Lin; Jennifer A Fleming; Emily J Furumoto; Robert F Roberts; Penny M Kris-Etherton; Connie J Rogers
Journal:  Eur J Nutr       Date:  2015-11-30       Impact factor: 5.614

3.  Safety of Bifidobacterium animalis Subsp. Lactis (B. lactis) Strain BB-12-Supplemented Yogurt in Healthy Children.

Authors:  Tina P Tan; Zhaoyong Ba; Mary E Sanders; Frank J D'Amico; Robert F Roberts; Keisha H Smith; Daniel J Merenstein
Journal:  J Pediatr Gastroenterol Nutr       Date:  2017-02       Impact factor: 2.839

4.  Bifidobacterium animalis subsp. lactis BB-12 Protects against Antibiotic-Induced Functional and Compositional Changes in Human Fecal Microbiome.

Authors:  Daniel Merenstein; Claire M Fraser; Robert F Roberts; Tian Liu; Silvia Grant-Beurmann; Tina P Tan; Keisha Herbin Smith; Tom Cronin; Olivia A Martin; Mary Ellen Sanders; Sean C Lucan; Maureen A Kane
Journal:  Nutrients       Date:  2021-08-17       Impact factor: 6.706

5.  Probiotics for respiratory tract infections in children attending day care centers-a systematic review.

Authors:  Rikke Pilmann Laursen; Iva Hojsak
Journal:  Eur J Pediatr       Date:  2018-05-12       Impact factor: 3.183

6.  Mismatch between Probiotic Benefits in Trials versus Food Products.

Authors:  Mary J Scourboutakos; Beatriz Franco-Arellano; Sarah A Murphy; Sheida Norsen; Elena M Comelli; Mary R L'Abbé
Journal:  Nutrients       Date:  2017-04-19       Impact factor: 5.717

7.  Effects of Bifidobacterium animalis subsp. lactis BB-12® on the lipid/lipoprotein profile and short chain fatty acids in healthy young adults: a randomized controlled trial.

Authors:  Yujin Lee; Zhaoyong Ba; Robert F Roberts; Connie J Rogers; Jennifer A Fleming; Huicui Meng; Emily J Furumoto; Penny M Kris-Etherton
Journal:  Nutr J       Date:  2017-06-29       Impact factor: 3.271

Review 8.  Guidance on the use of probiotics in clinical practice in children with selected clinical conditions and in specific vulnerable groups.

Authors:  Iva Hojsak; Valentina Fabiano; Tudor Lucian Pop; Olivier Goulet; Gian Vincenzo Zuccotti; Fugen Cullu Çokuğraş; Massimo Pettoello-Mantovani; Sanja Kolaček
Journal:  Acta Paediatr       Date:  2018-04-16       Impact factor: 2.299

Review 9.  Probiotics in Children: What Is the Evidence?

Authors:  Iva Hojsak
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2017-09-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.